DBV Technologies S.A. (DBVT)

Focuses on immunotherapy treatments for food allergies.

DBVT Stock Quote

Company Report

DBV Technologies S.A., a clinical-stage biopharmaceutical company headquartered in Montrouge, France, specializes in the development of epicutaneous immunotherapy products aimed at treating food allergies and other immune-related disorders. The company's flagship product candidate, Viaskin Peanut, has completed Phase III clinical trials and targets the treatment of peanut allergies in children aged 4 to 11 years, adolescents, and adults. DBV Technologies is also advancing Viaskin Milk through Phase I/II clinical trials for Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA), and has a pre-clinical stage product, Viaskin Egg, in development for hen's egg allergy.

Beyond its food allergy focus, DBV Technologies is actively engaged in several earlier stage research initiatives. These include a vaccine for Bordetella pertussis, commonly known as whooping cough, and ongoing research programs exploring potential treatments for respiratory syncytial virus, Crohn's disease, celiac disease, and type I diabetes. The company collaborates with Nestle Health Science to develop MAG1C, an atopy patch test designed to diagnose non-IgE mediated CMPA in infants and toddlers, underscoring its commitment to advancing diagnostic capabilities alongside therapeutic innovations.

Founded in 2002, DBV Technologies has established itself as a leader in the field of epicutaneous immunotherapy, leveraging its expertise to address significant unmet medical needs in allergy management. With a robust pipeline and strategic collaborations, DBV Technologies continues to pursue groundbreaking solutions that aim to improve the quality of life for patients affected by food allergies and related conditions worldwide.

DBVT EPS Chart

DBVT Revenue Chart

Stock Research

TRP BASE RPD NYT ZD SBCF MMM

DBVT Chart

View interactive chart for DBVT

DBVT Profile

DBVT News

Analyst Ratings